Header Ads

Can regulators really keep up with vaping?

Prognosis
Bloomberg

Teen e-cigarette use is surging after years of persuading kids not to smoke. Regulators blamed sweet flavors and promised to sweep the market of products they say lure teens to vaping. They missed some.  

Walk into any vape shop or convenience store and you can see them: A crop of new all-in-one products that are exempt from the policy. One of the most popular brands, Puff Bar, sells about two dozen flavors, including Blue Razz and O.M.G. (that's orange, mango, guava). The company behind Puff Bar this week said it has "ceased all distribution" and plans to file an application with regulators to reintroduce its products.

That doesn't mean the fakes are throwing in the towel. Puff Bar is already battling counterfeits and knockoffs, something even vaping behemoth Juul struggles to combat. A thriving market of impostors means regulators are likely to continue finding themselves one step behind.

Both the public-health and vaping communities blame regulators for allowing upstart brands like Puff Bar to hit shelves. The e-cigarette market was essentially frozen in August 2016, but that hasn't stopped companies from jumping into the booming industry.

What's more, the pace of innovation around vaping is picking up (and consumers are eager to give new products a try). Puff Bar's website features a silicone cap that consumers can snap on to USB-shaped devices and release flavors like peach ice or sour apple. A number of Puff-related trademarks have been recently filed, including Puff CBD. 

A shake out may be on the horizon. Companies must submit applications to the Food and Drug Administration by May 12 if they want to stay on the market. Big questions loom for the agency, including how it plans to catch and remove illegal products in the seemingly endless game of public health whack-a-mole.—Angelica LaVito

Here's what else we're watching:

Case count. The number of new coronavirus cases reported by Hubei province sank after China again changed the way it reports the number of infections. But the change raises questions over the reliability of data from the epicenter of the outbreak.

Elsewhere on the coronavirus front:

  • South Korea reported its first death and a surge of new cases.
  • Infections are also climbing in Japan, a new hotbed.

Flu (non-coronavirus division). This season's influenza vaccine was particularly well-suited for children, the CDC said, preventing many of the most severe infections.

Opioid subpoena. CVS said it received a federal subpoena asking about its handing of opioids and other controlled substances. It's a signal that addressing the addiction epidemic remains a top priority for U.S. officials.

Listen up. On the latest season on the Prognosis podcast, we tell how the $4 trillion American health-care system became so expensive and inefficient, and what some people are trying to do about it. Download it here on Apple devices, and here on Android.

Got this newsletter forwarded to you? Sign up to get it every Thursday by clicking here

We want to hear from you. If you have feedback, questions or potential story ideas, reach out to me at alavito@bloomberg.net

 

Like Bloomberg's Prognosis? Subscribe to Bloomberg.com. You'll get our unmatched global news coverage and two premium daily newsletters, The Bloomberg Open and The Bloomberg Close, and much, much more. See our limited-time introductory offer.

Download the Bloomberg app: It's available for iOS and Android.

Before it's here, it's on the Bloomberg Terminal. Find out more about how the Terminal delivers information and analysis that financial professionals can't find anywhere else. Learn more.

 

No comments